GH Research/$GHRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GH Research
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Ticker
$GHRS
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Dublin, Ireland
Employees
50
ISIN
IE000GID8VI0
Website
GH Research Metrics
BasicAdvanced
$756M
-
-$0.79
0.97
-
Price and volume
Market cap
$756M
Beta
0.97
52-week high
$20.50
52-week low
$6.00
Average daily volume
187K
Financial strength
Current ratio
29.71
Quick ratio
29.376
Long term debt to equity
0.104
Total debt to equity
0.212
Interest coverage (TTM)
-72.16%
Profitability
EBITDA (TTM)
-51.455
Management effectiveness
Return on assets (TTM)
-11.97%
Return on equity (TTM)
-16.20%
Valuation
Price to book
2.44
Price to tangible book (TTM)
2.44
Price to free cash flow (TTM)
-15.798
Free cash flow yield (TTM)
-6.33%
Free cash flow per share (TTM)
-77.16%
Growth
Earnings per share change (TTM)
26.64%
3-year earnings per share growth (CAGR)
40.87%
What the Analysts think about GH Research
Analyst ratings (Buy, Hold, Sell) for GH Research stock.
Bulls say / Bears say
GH Research's lead product candidate, GH001, demonstrated a significant placebo-adjusted reduction of -15.5 points on the MADRS scale in a Phase 2b trial for treatment-resistant depression, with 57.5% of patients achieving remission by Day 8. (GH Research News Release)
The company successfully raised $150 million through a public offering priced at $15 per share, strengthening its financial position to support ongoing clinical development. (GH Research News Release)
Analysts from Guggenheim initiated coverage on GH Research with a 'buy' rating and a $32.00 price target, indicating confidence in the company's growth prospects. (American Banking and Market News)
The recent $150 million public offering at $15 per share represents an 8% discount to the current market price, leading to approximately 18.3% dilution for existing shareholders. (StockTitan)
Despite positive trial results, GH Research remains a clinical-stage company with no approved products, posing inherent risks associated with drug development and regulatory approval processes. (Nasdaq)
The stock experienced significant volatility, with an 88.8% surge following trial results, which may indicate speculative trading and potential for sharp corrections. (Market Chameleon)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
GH Research Financial Performance
Revenues and expenses
GH Research Earnings Performance
Company profitability
GH Research News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GH Research stock?
GH Research (GHRS) has a market cap of $756M as of July 01, 2025.
What is the P/E ratio for GH Research stock?
The price to earnings (P/E) ratio for GH Research (GHRS) stock is 0 as of July 01, 2025.
Does GH Research stock pay dividends?
No, GH Research (GHRS) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next GH Research dividend payment date?
GH Research (GHRS) stock does not pay dividends to its shareholders.
What is the beta indicator for GH Research?
GH Research (GHRS) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.